Hepatitis a virus

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Hollinger, F Blaine ^a   Martin, Annette ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974658532     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (420)

1. Aach RD, Evans J, Losee J. An epidemic of infectious hepatitis possibly due to airborne transmission. Am J Epidemiol 1968;87:99-109.
2. Abe H, Beninger PR, Ikejiri N, et al. Light microscopic findings of liver biopsy specimens from patients with hepatitis type A and comparison with type B. Gastroenterology 1982;82:938-947.
3. Allaire M, Chernaia MM, Malcolm BA, et al. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 1994;369:72-76.
4. Amado LA, Marchevsky RS, de Paula VS, et al. Experimental hepatitis A virus (HAV) infection in cynomolgus monkeys (Macaca fascicularis): evidence of active extrahepatic site of HAV replication. Int J Exp Pathol 2010;91:87-97.
5. Amado LA, Villar LM, de Paula VS, et al. Exposure to multiple subgenotypes of hepatitis A virus during an outbreak using matched serum and saliva specimens. J Med Virol 2011;83:768-775.
6. Ambrosch F, Andre FE, Delem A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992;10(Suppl 1):S142-S145.
7. Ambrosch F, Wiedermann G, Andre FE, et al. Comparison of HAV antibodies induced by vaccination, passive immunization, and natural infection. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:98-100.
8. Amon JJ, Devasia R, Xia G, et al. Molecular epidemiology of foodborne hepatitis A outbreaks in the United States, 2003. J Infect Dis 2005;192:1323-1330.
9. Anderson DA, Ross BC. Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J Virol 1990;64:5284-5289.
10. Andre FE, D'Hondt E, Delem A, et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992;10(Suppl 1):S160-S168.
11. Andre FE, Hepburn A, D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol 1990;37:72-95.
12. Aragones L, Guix S, Ribes E, et al. Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid. PLoS Pathog 2010;6:e1000797.
13. Asher LV, Binn LN, Mensing TL, et al. Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J Med Virol 1995;47:260-268.
14. Ashida M, Hamada C. Molecular cloning of the hepatitis A virus receptor from a simian cell line. J Gen Virol 1997;78(Pt 7):1565-1569.
15. Azimi PH, Roberto RR, Guralnik J, et al. Transfusion-acquired hepatitis A in a premature infant with secondary nosocomial spread in an intensive care nursery. Am J Dis Child 1986;140:23-27.
16. Baba M, Hasegawa H, Nakayabu M, et al. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. J Clin Lab Immunol 1993;40:47-60.
17. Baer GM, Walker JA. Studies of an outbreak of acute hepatitis A: I. Complement level fluctuation. J Med Virol 1977;1:1-7.
18. Balayan MS. Natural hosts of hepatitis A virus. Vaccine 1992;10(Suppl 1):S27-S31.
19. Barbara JA, Howell DR, Briggs M, et al. Post-transfusion hepatitis A. Lancet 1982;1:738.
20. Beales LP, Holzenburg A, Rowlands DJ. Viral internal ribosome entry site structures segregate into two distinct morphologies. J Virol 2003;77:6574-6579.
21. Beard MR, Cohen L, Lemon SM, et al. Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J Virol 2001;75:1414-1426.
22. Beneduce F, Ciervo A, Kusov Y, et al. Mapping of protein domains of hepatitis A virus 3AB essential for interaction with 3CD and viral RNA. Virology 1999;264:410-421.
23. Bergmann EM, Mosimann SC, Chernaia MM, et al. The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition. J Virol 1997;71:2436-2448.
24. Bienzle U, Bock HL, Kruppenbacher JP, et al. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response. Vaccine 1996;14:501-505.
25. Bishop NE, Anderson DA. Early interactions of hepatitis A virus with cultured cells: viral elution and the effect of pH and calcium ions. Arch Virol 1997;142:2161-2178.
26. Bishop NE, Anderson DA. RNA-dependent cleavage of VP0 capsid protein in provirions of hepatitis A virus. Virology 1993;197:616-623.
27. Bishop NE, Anderson DA. Uncoating kinetics of hepatitis A virus virions and provirions. J Virol 2000;74:3423-3426.
28. Blank CA, Anderson DA, Beard M, et al. Infection of polarized cultures of human intestinal epithelial cells with hepatitis A virus: vectorial release of progeny virions through apical cellular membranes. J Virol 2000;74:6476-6484.
29. Blum AL, Stutz R, Haemmerli UP, et al. A fortuitously controlled study of steroid therapy in acute viral hepatitis. I. Acute disease. Am J Med 1969;47:82-92.
30. Boggs JD, Melnick JL, Conrad ME, et al. Viral hepatitis. Clinical and tissue culture studies. JAMA 1970;214:1041-1046.
31. Borman AM, Kean KM. Intact eukaryotic initiation factor 4G is required for hepatitis A virus internal initiation of translation. Virology 1997;237:129-136.
32. Borman AM, Le Mercier P, Girard M, et al. Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 1997;25:925-932.
33. Borovec SV, Anderson DA. Synthesis and assembly of hepatitis A virus-specific proteins in BS-C-1 cells. J Virol 1993;67:3095-3102.
34. Bosch A, Gonzalez-Dankaart JF, Haro I, et al. A new continuous epitope of hepatitis A virus. J Med Virol 1998;54:95-102.
35. Bower WA, Nainan OV, Han X, et al. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000;182:12-17.
36. Boyer JL, Klatskin G. Pattern of necrosis in acute viral hepatitis-prognostic value of bridging (subacute hepatic necrosis). N Engl J Med 1970;283:1063-1071.
37. Brack K, Berk I, Magulski T, et al. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA. J Virol 2002;76:11920-11930.
38. Brack K, Frings W, Dotzauer A, et al. A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J Virol 1998;72:3370-3376.
39. Bradley DW, Maynard JE, Hindman SH, et al. Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J Clin Microbiol 1977;5:521-530.
40. Bradley DW, Schable CA, McCaustland KA, et al. Hepatitis A virus: growth characteristics of in vivo and in vitro propagated wild and attenuated virus strains. J Med Virol 1984;14:373-386.
41. Brown EA, Day SP, Jansen RW, et al. The 5' nontranslated region of hepatitis A virus RNA: secondary structure and elements required for translation in vitro. J Virol 1991;65:5828-5838.
42. Brown EA, Jansen RW, Lemon SM. Characterization of a simian hepatitis A virus (HAV): antigenic and genetic comparison with human HAV. J Virol 1989;63:4932-4937.
43. Brown EA, Zajac AJ, Lemon SM. In vitro characterization of an internal ribosomal entry site (IRES) present within the 5' nontranslated region of hepatitis A virus RNA: comparison with the IRES of encephalomyocarditis virus. J Virol 1994;68:1066-1074.
44. Bubeck D, Filman DJ, Cheng N, et al. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 2005;79:7745-7755.
45. Burke DS, Heisey GB. Wild Malaysian cynomolgus monkeys are exposed to hepatitis A virus. Am J Trop Med Hyg 1984;33:940-944.
46. Centers for Disease Control and Prevention. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56:1080-1084.
47. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2007. MMWR 2009;58:1-27.
48. Centers for Disease Control and Prevention. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47:1-57.
49. Centers for Disease Control and Prevention. Viral hepatitis statistics and surveillance-surveillance data for acute viral hepatitis-United States, 2008. Atlanta: Centers for Disease Control and Prevention; 2010.
50. Chalmers TC, Eckhardt RD, Reynolds WE, et al. The treatment of acute infectious hepatitis. Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J Clin Invest 1955;34:1163-1235.
51. Chang KH, Brown EA, Lemon SM. Cell type-specific proteins which interact with the 5' nontranslated region of hepatitis A virus RNA. J Virol 1993;67:6716-6725.
52. Chatenoud L, Bach JF. Genetic control of hepatitis A severity and susceptibility to allergy. J Clin Invest 2011;121:848-850.
53. Chenard-Neu MP, Boudjema K, Bernuau J, et al. Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure-a multicenter European study. Hepatology 1996;23:1119-1127.
54. Cockayne EA. Catarrhal jaundice, sporadic and epidemic, and its relation to acute yellow atrophy of the liver. Q J Med 1912;6:1-28.
55. Cohen JI, Feinstone S, Purcell RH. Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs. J Infect Dis 1989;160:887-890.
56. Cohen JI, Rosenblum B, Feinstone SM, et al. Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J Virol 1989;63:5364-5370.
57. Cohen JI, Rosenblum B, Ticehurst JR, et al. Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A 1987;84:2497-2501.
58. Cohen JI, Ticehurst JR, Feinstone SM, et al. Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol 1987;61:3035-3039.
59. Cohen JI, Ticehurst JR, Purcell RH, et al. Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol 1987;61:50-59.
60. Cohen L, Benichou D, Martin A. Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis. J Virol 2002;76:7495-7505.
61. Cordes S, Kusov Y, Heise T, et al. La autoantigen suppresses IRES-dependent translation of the hepatitis A virus. Biochem Biophys Res Commun 2008;368:1014-1019.
62. Costa-Mattioli M, Cristina J, Romero H, et al. Molecular evolution of hepatitis A virus: a new classification based on the complete VP1 protein. J Virol 2002;76:9516-9525.
63. Coulepis AG, Anderson BN, Gust ID. Hepatitis A. Adv Virus Res 1987;32:129-169.
64. Coulepis AG, Locarnini SA, Lehmann NI, et al. Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J Infect Dis 1980;141:151-156.
65. Coulepis AG, Tannock GA, Locarnini SA, et al. Evidence that the genome of hepatitis A virus consists of single-stranded RNA. J Virol 1981;37:473-477.
66. Counihan NA, Daniel LM, Chojnacki J, et al. Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-cytopathic and minimally cytopathic viruses. J Virol Methods 2006;133:62-69.
67. Cristina J, Costa-Mattioli M. Genetic variability and molecular evolution of hepatitis A virus. Virus Res 2007;127:151-157.
68. Cromeans T, Fields HA, Sobsey MD. Replication kinetics and cytopathic effect of hepatitis A virus. J Gen Virol 1989;70(Pt 8):2051-2062.
69. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001;14:38-58.
70. D'Hondt E, Purcell RH, Emerson SU, et al. Efficacy of an inactivated hepatitis A vaccine in pre- and postexposure conditions in marmosets. J Infect Dis 1995;171(Suppl 1):S40-S43.
71. Daemer RJ, Feinstone SM, Gust ID, et al. Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun 1981;32:388-393.
72. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000;19:1045-1052.
73. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-210.
74. Davenport FM, Hennessy AV, Christopher N, et al. A common source multi-household outbreak of chimpanzee-associated hepatitis in humans. Am J Epidemiol 1966;83:146-151.
75. Day SP, Murphy P, Brown EA, et al. Mutations within the 5' nontranslated region of hepatitis A virus RNA which enhance replication in BS-C-1 cells. J Virol 1992;66:6533-6540.
76. De Jong AS, de Mattia F, Van Dommelen MM, et al. Functional analysis of picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking. J Virol 2008;82:3782-3790.
77. Decker RH, Kosakowski SM, Vanderbilt AS, et al. Diagnosis of acute hepatitis A by HAVAB-M, a direct radioimmunoassay for IgM anti-HAV. Am J Clin Pathol 1981;76:140-147.
78. Deinhardt F, Courtois G, Dherte P, et al. Studies of liver function tests in chimpanzees after inoculation with human infectious hapatitis virus. Am J Hyg 1962;75:311-321.
79. Deinhardt F, Holmes AW, Capps RB, et al. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. J Exp Med 1967;125:673-688.
80. Dentinger CM, Bower WA, Nainan OV, et al. An outbreak of hepatitis A associated with green onions. J Infect Dis 2001;183:1273-1276.
81. Dienstag JL, Davenport FM, McCollum RW, et al. Nonhuman primate-associated viral hepatitis type A. Serologic evidence of hepatitis A virus infection. JAMA 1976;236:462-464.
82. Dienstag JL, Feinstone SM, Purcell RH, et al. Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis 1975;132:532-545.
83. Dienstag JL, Routenberg JA, Purcell RH, et al. Foodhandler-associated outbreak of hepatitis type A. An immune electron microscopic study. Ann Intern Med 1975;83:647-650.
84. Dolja VV, Carrington JC. Evolution of positive-strand RNA viruses. Semin Virol 1992;3:315-326.
85. Dollenmaier G, Weitz M. Interaction of glyceraldehyde-3-phosphate dehydrogenase with secondary and tertiary RNA structural elements of the hepatitis A virus 3' translated and non-translated regions. J Gen Virol 2003;84:403-414.
86. Dotzauer A, Brenner M, Gebhardt U, et al. IgA-coated particles of hepatitis A virus are translocalized antivectorially from the apical to the basolateral site of polarized epithelial cells via the polymeric immunoglobulin receptor. J Gen Virol 2005;86:2747-2751.
87. Dotzauer A, Feinstone SM, Kaplan G. Susceptibility of nonprimate cell lines to hepatitis A virus infection. J Virol 1994;68:6064-6068.
88. Dotzauer A, Gebhardt U, Bieback K, et al. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J Virol 2000;74:10950-10957.
89. Drake ME, Ming C. Gamma globulin in epidemic hepatitis: comparative value of two dosage levels, apparently near the minimal effective level. J Am Med Assoc 1954;155:1302-1305.
90. Ellsbury E, Owosckun D, Mackey K, et al. Outbreak of viral hepatitis in the staff of a pediatric ward-California. MMWR Morb Mortal Wkly Rep 1977;26:77-78.
91. Emerson SU, Huang YK, McRill C, et al. Mutations in both the 2B and 2C genes of hepatitis A virus are involved in adaptation to growth in cell culture. J Virol 1992;66:650-654.
92. Emerson SU, Huang YK, Nguyen H, et al. Identification of VP1/2A and 2C as virulence genes of hepatitis A virus and demonstration of genetic instability of 2C. J Virol 2002;76:8551-8559.
93. Emerson SU, Huang YK, Purcell RH. 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology 1993;194:475-480.
94. Emerson SU, Tsarev SA, Govindarajan S, et al. A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees. J Infect Dis 1996;173:592-597.
95. Emini EA, Hughes JV, Perlow DS, et al. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985;55:836-839.
96. Enriquez R, Frosner GG, Hochstein-Mintzel V, et al. Accumulation and persistence of hepatitis A virus in mussels. J Med Virol 1992;37:174-179.
97. Ertem D, Acar Y, Arat C, et al. Thrombotic and thrombocytopenic complications secondary to hepatitis A infection in children. Am J Gastroenterol 1999;94:3653-3655.
98. Evans AS, Sprinz H, Nelson RS. Adrenal hormone therapy in viral hepatitis. I. The effect of ACTH in the acute disease. Ann Intern Med 1953;38:1115-1133.
99. Evans AS, Sprinz H, Nelson RS. Adrenal hormone therapy in viral hepatitis. II. The effect of cortisone in the acute disease. Ann Intern Med 1953;38:1134-1147.
100. Feigelstock D, Thompson P, Mattoo P, et al. The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol 1998;72:6621-6628.
101. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973;182:1026-1028.
102. Fensterl V, Grotheer D, Berk I, et al. Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J Virol 2005;79:10968-10977.
103. Ferrell LD, Theise ND, Scheuer PJ. Acute and chronic viral hepatitis. In: MacSween RNM, Portmann BC, Ishak KG, et al, eds. Pathology of the Liver. London: Churchill Livingstone; 2002:314-325.
104. Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004;38:705-715.
105. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003;22:354-359.
106. Flehmig B. Hepatitis A-virus in cell culture: I. propagation of different hepatitis A-virus isolates in a fetal rhesus monkey kidney cell line (Frhk-4). Med Microbiol Immunol 1980;168:239-248.
107. Flehmig B, Mauler RF, Noll G, et al. Progress in the development of an attenuated, live hepatitis A vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss; 1988:87-90.
108. Fleischer B, Fleischer S, Maier K, et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990;69:14-19.
109. Frosner GG, Overby LR, Flehmig B, et al. Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol 1977;1:163-173.
110. Frosner GG, Papaevangelou G, Butler R, et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. Am J Epidemiol 1979;110:63-69.
111. Fujiwara K, Yokosuka O, Ehata T, et al. Association between severity of type A hepatitis and nucleotide variations in the 5' non-translated region of hepatitis A virus RNA: strains from fulminant hepatitis have fewer nucleotide substitutions. Gut 2002;51:82-88.
112. Fujiwara K, Yokosuka O, Ehata T, et al. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology 1997;26:1634-1639.
113. Fujiwara K, Yokosuka O, Imazeki F, et al. Analysis of hepatitis A virus protein 2B in sera of hepatitis A of various severities. J Gastroenterol 2007;42:560-566.
114. Fujiyama S, Iino S, Odoh K, et al. Time course of hepatitis A virus antibody titer after active and passive immunization. Hepatology 1992;15:983-988.
115. Funkhouser AW, Purcell RH, D'Hondt E, et al. Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. J Virol 1994;68:148-157.
116. Funkhouser AW, Raychaudhuri G, Purcell RH, et al. Progress toward the development of a genetically engineered attenuated hepatitis A virus vaccine. J Virol 1996;70:7948-7957.
117. Funkhouser AW, Schultz DE, Lemon SM, et al. Hepatitis A virus translation is rate-limiting for virus replication in MRC-5 cells. Virology 1999;254:268-278.
118. Gabriel P, Vallbracht A, Flehmig B. Lack of complement-dependent cytolytic antibodies in hepatitis A virus infection. J Med Virol 1986;20:23-31.
119. Gabrieli R, Sanchez G, Macaluso A, et al. Hepatitis in Albanian children: molecular analysis of hepatitis A virus isolates. J Med Virol 2004;72:533-537.
120. Gauss-Muller V, Lottspeich F, Deinhardt F. Characterization of hepatitis A virus structural proteins. Virology 1986;155:732-736.
121. Gazzard BG, Portmann B, Murray-Lyon IM, et al. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q J Med 1975;44:615-626.
122. Gellis SS, Stokes JJ, Brother GM, et al. The use of human immune serum globulin (gamma globulin) in infectious (epidemic) hepatitis in the Mediterranean theater of operations. I. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA 2011;128:1062-1063.
123. Gharbi-Khelifi H, Sdiri K, Harrath R, et al. Genetic analysis of HAV strains in Tunisia reveals two new antigenic variants. Virus Genes 2007;35:155-159.
124. Giles JP, Liebhaber H, Krugman S, et al. Early viremia and viruria in infectious hepatitis. Virology 1964;24:107-108.
125. Glass MJ, Jia XY, Summers DF. Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5' noncoding region. Virology 1993;193:842-852.
126. Gorbalenia AE, Blinov VM, Kunin EV. [Prediction of the nucleotide-binding properties of viral proteins from their primary structure]. Mol Gen Mikrobiol Virusol 1985;30-36.
127. Gordon SC, Reddy KR, Schiff L, et al. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984;101:635-637.
128. Gosert R, Cassinotti P, Siegl G, et al. Identification of hepatitis A virus non-structural protein 2B and its release by the major virus protease 3C. J Gen Virol 1996;77(Pt 2):247-255.
129. Gosert R, Chang KH, Rijnbrand R, et al. Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites in vivo. Mol Cell Biol 2000;20:1583-1595.
130. Gosert R, Egger D, Bienz K. A cytopathic and a cell culture adapted hepatitis A virus strain differ in cell killing but not in intracellular membrane rearrangements. Virology 2000;266:157-169.
131. Goswami BB, Kulka M, Ngo D, et al. Apoptosis induced by a cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA degradation but occurs in the absence of 2'-5' oligoadenylate synthetase. Antiviral Res 2004;63:153-166.
132. Gotsman I, Muszkat M. Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis A. J Gastroenterol Hepatol 2001;16:1239-1243.
133. Graff J, Cha J, Blyn LB, et al. Interaction of poly(rC) binding protein 2 with the 5' noncoding region of hepatitis A virus RNA and its effects on translation. J Virol 1998;72:9668-9675.
134. Graff J, Emerson SU. Importance of amino acid 216 in nonstructural protein 2B for replication of hepatitis A virus in cell culture and in vivo. J Med Virol 2003;71:7-17.
135. Graff J, Kasang C, Normann A, et al. Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation. Virology 1994;204:60-68.
136. Graff J, Normann A, Feinstone SM, et al. Nucleotide sequence of wild-type hepatitis A virus GBM in comparison with two cell culture-adapted variants. J Virol 1994;68:548-554.
137. Graff J, Normann A, Flehmig B. Influence of the 5' noncoding region of hepatitis A virus strain GBM on its growth in different cell lines. J Gen Virol 1997;78(Pt 8):1841-1849.
138. Graff J, Richards OC, Swiderek KM, et al. Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. J Virol 1999;73:6015-6023.
139. Gupta DN, Smetana HF. The histopathology of viral hepatitis as seen in the Delhi epidemic (1955-56). Indian J Med Res 1957;45:101-113.
140. Gust ID, Lehmann NI, Crowe S, et al. The origin of the HM175 strain of hepatitis A virus. J Infect Dis 1985;151:365-367.
141. Gust ID, Lehmann NI, Dimitrakakis M. A seroepidemiologic study of infection with HAV and HBV in five Pacific Islands. Am J Epidemiol 1979;110:237-242.
142. Gust ID, Lehmann NI, Lucas CR. Relationship between prevalence of antibody to hepatitis A antigen and age: a cohort effect? J Infect Dis 1978;138:425-426.
143. Guthrie L. Epidemic catarrhal jaundice. Proc R Soc Med 1913;6:48-56.
144. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:14-20.
145. Hall WT, Bradley DW, Madden DL, et al. Comparison of sensitivity of radioimmunoassay and immune electron microscopy for detecting hepatitis A antigen in fecal extracts. Proc Soc Exp Biol Med 1977;155:193-198.
146. Hall WT, Madden DL, Mundon FK, et al. Protective effect of immune serum globulin (ISG) against hepatitis A infection in a natural epidemic. Am J Epidemiol 1977;106:72-75.
147. Hamilton V. Follow-up on shellfish-associated hepatitis: southern United States. 1973;22:388.
148. Harden AG, Barondess JA, Parker B. Transmission of infectious hepatitis by transfusion of whole blood; with a note on the early appearance of viremia in this disease. N Engl J Med 1955;253:923-925.
149. Hardin CC, Sneeden JL, Lemon SM, et al. Folding of pyrimidine-enriched RNA fragments from the vicinity of the internal ribosomal entry site of hepatitis A virus. Nucleic Acids Res 1999;27:665-673.
150. Harmon SA, Richards OC, Summers DF, et al. The 5'-terminal nucleotides of hepatitis A virus RNA, but not poliovirus RNA, are required for infectivity. J Virol 1991;65:2757-2760.
151. Harmon SA, Updike W, Jia XY, et al. Polyprotein processing in cis and in trans by hepatitis A virus 3C protease cloned and expressed in Escherichia coli. J Virol 1992;66:5242-5247.
152. Havens WP, Jr. Period of infectivity of patients with experimentally induced infectious hepatitis. J Exp Med 1946;83:251-258.
153. Havens WP, Jr. The etiology of infectious hepatitis. J Am Med Assoc 1947;134:653-655.
154. Havens WP, Jr. Viral hepatitis. Postgrad Med J 1963;39:212-223.
155. Havens WP, Jr., Marck RE. The leukocytic response of patients with experimentally induced infectious hepatitis. Am J Med Sci 1946;212:138.
156. Havens WP, Jr., Paul JR. Prevention of infectious hepatitis with gama globulin. JAMA 1945;129:272.
157. Henkin RI, Smith FR. Hyposmia in acute viral hepatitis. Lancet 1971;1:823-826.
158. Herold J, Andino R. Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol Cell 2001;7:581-591.
159. Hillis WD. An outbreak of infectious hepatitis among chimpanzee handlers at a United States Air Force Base. Am J Hyg 1961;73:316-328.
160. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 1985;229:1358-1365.
161. Hollinger FB. International symposium on active immunization against hepatitis A. Vaccine 1992;10(Suppl 1):S6-S7.
162. Hollinger FB, Bradley DW, Dreesman GR, et al. Detection of viral hepatitis type A. Am J Clin Pathol 1976;65:854-865.
163. Hollinger FB, Grander JW, Nickel FR, et al. Hepatitis B prevalence within a dental student population. J Am Dent Assoc 1977;94:521-527.
164. Hollinger FB, Khan NC, Oefinger PE, et al. Posttransfusion hepatitis type A. JAMA 1983;250:2313-2317.
165. Holmes AW, Wolfe L, Rosenblate H, et al. Hepatitis in marmosets: induction of disease with coded specimens from a human volunteer study. Science 1969;165:816-817.
166. Hornei B, Kammerer R, Moubayed P, et al. Experimental hepatitis A virus infection in guinea pigs. J Med Virol 2001;64:402-409.
167. Hu MD. [Observation of live, attenuated hepatitis A vaccines in humans]. Zhonghua Yu Fang Yi Xue Za Zhi 1993;27:65-68.
168. Hu MD, Scheid R, Deinhardt F, et al. Attenuated hepatitis A virus for vaccine development: attenuation and virulence for marmosets. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss; 1988:81-82.
169. Huang SN, Lorenz D, Gerety RJ. Electron and immunoelectron microscopic study on liver tissues of marmosets infected with hepatitis A virus. Lab Invest 1979;41:63-71.
170. Hughes JV, Stanton LW. Isolation and immunizations with hepatitis A viral structural proteins: induction of antiprotein, antiviral, and neutralizing responses. J Virol 1985;55:395-401.
171. Hughes JV, Stanton LW, Tomassini JE, et al. Neutralizing monoclonal antibodies to hepatitis A virus: partial localization of a neutralizing antigenic site. J Virol 1984;52:465-473.
172. Hutin YJ, Pool V, Cramer EH, et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 1999;340:595-602.
173. Ibe M, Rude B, Gerken G, et al. Coombs-negative severe hemolysis associated with hepatitis A. Z Gastroenterol 1997;35:567-569.
174. Inman RD, Hodge M, Johnston ME, et al. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 1986;105:700-703.
175. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-1334.
176. Ishak KG. Light microscopic morphology of viral hepatitis. Am J Clin Pathol 1976;65 Suppl 5:787-827.
177. Iwarson S, Frosner G, Lindholm A, et al. The changed epidemiology of hepatitis A infection in Scandinavia. Scand J Infect Dis 1978;10:155-156.
178. Jacobsen KH. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Geneva, Switzerland: World Health Organization; 2009.
179. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010;28:6653-6657.
180. Jakschies D, Zachoval R, Muller R, et al. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 1994;19:857-865.
181. Jansen RW, Siegl G, Lemon SM. Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proc Natl Acad Sci U S A 1990;87:2867-2871.
182. Jewell DA, Swietnicki W, Dunn BM, et al. Hepatitis A virus 3C proteinase substrate specificity. Biochemistry 1992;31:7862-7869.
183. Jia XY, Summers DF, Ehrenfeld E. Host antibody response to viral structural and nonstructural proteins after hepatitis A virus infection. J Infect Dis 1992;165:273-280.
184. Jia XY, Summers DF, Ehrenfeld E. Primary cleavage of the HAV capsid protein precursor in the middle of the proposed 2A coding region. Virology 1993;193:515-519.
185. Jia XY, Tesar M, Summers DF, et al. Replication of hepatitis A viruses with chimeric 5' nontranslated regions. J Virol 1996;70:2861-2868.
186. Jones AE, Smith JL, Hindman SH, et al. Foodborne hepatitis A infection: a report of two urban restaurant-associated outbreaks. Am J Epidemiol 1977;105:156-162.
187. Joseph PR, Millar JD, Henderson DA. An outbreak of hepatitis traced to food contamination. N Engl J Med 1965;273:188-194.
188. Jung YM, Park SJ, Kim JS, et al. Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea. J Med Virol 2010;82:1318-1326.
189. Kanda T, Gauss-Muller V, Cordes S, et al. Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein. J Viral Hepat 2010;17:618-623.
190. Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 1984;4:933-936.
191. Kaplan G, Totsuka A, Thompson P, et al. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. Embo J 1996;15:4282-4296.
192. Kaplan JE, Nelson DB, Schonberger LB, et al. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ 1984;62:585-590.
193. Karron RA, Daemer R, Ticehurst J, et al. Studies of prototype live hepatitis A virus vaccines in primate models. J Infect Dis 1988;157:338-345.
194. Karvountzis GG, Redeker AG, Peters RL. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 1974;67:870-877.
195. Katz R, Velasco M, Guzman C, et al. Red cell survival estimated by radioactive chromium in hepatobiliary disease. Gastroenterology 1964;46:399-404.
196. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-205.
197. Khan NC, Hollinger FB, Melnick JL. Localization of hepatitis A virus antigen to specific subcellular fractions of hepatitis-A-infected chimpanzee liver cells. Intervirology 1984;21:187-194.
198. Kim HY, Eyheramonho MB, Pichavant M, et al. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. J Clin Invest 2011;121:1111-1118.
199. Kim SJ, Jang MH, Stapleton JT, et al. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 2004;318:598-607.
200. Klein BS, Michaels JA, Rytel MW, et al. Nosocomial hepatitis A. A multinursery outbreak in Wisconsin. JAMA 1984;252:2716-2721.
201. Konduru K, Kaplan GG. Determinants in 3Dpol modulate the rate of growth of hepatitis A virus. J Virol 2010;84:8342-8347.
202. Konduru K, Kaplan GG. Stable growth of wild-type hepatitis A virus in cell culture. J Virol 2006;80:1352-1360.
203. Kozak M. Regulation of translation in eukaryotic systems. Annu Rev Cell Biol 1992;8:197-225.
204. Krawczynski KK, Bradley DW, Murphy BL, et al. Pathogenetic aspects of hepatitis A virus infection in enterally inoculated marmosets. Am J Clin Pathol 1981;76:698-706.
205. Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200:365-373.
206. Krugman S, Ward R, Giles JP, et al. Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection. N Engl J Med 1959;261:729-734.
207. Krugman S, Ward R, Giles JP. The natural history of infectious hepatitis. Am J Med 1962;32:717-728.
208. Kryger P, Christoffersen P. Liver histopathology of the hepatitis A virus infection: a comparison with hepatitis type B and non-A, non-B. J Clin Pathol 1983;36:650-654.
209. Kurane I, Binn LN, Bancroft WH, et al. Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J Immunol 1985;135:2140-2144.
210. Kusov Y, Gauss-Muller V. Improving proteolytic cleavage at the 3A/3B site of the hepatitis A virus polyprotein impairs processing and particle formation, and the impairment can be complemented in trans by 3AB and 3ABC. J Virol 1999;73:9867-9878.
211. Kusov YY, Gauss-Muller V. In vitro RNA binding of the hepatitis A virus proteinase 3C (HAV 3Cpro) to secondary structure elements within the 5' terminus of the HAV genome. RNA 1997;3:291-302.
212. Kusov YY, Gosert R, Gauss-Muller V. Replication and in vivo repair of the hepatitis A virus genome lacking the poly(A) tail. J Gen Virol 2005;86:1363-1368.
213. Kusov YY, Morace G, Probst C, et al. Interaction of hepatitis A virus (HAV) precursor proteins 3AB and 3ABC with the 5' and 3' termini of the HAV RNA. Virus Res 1997;51:151-157.
214. Lanford RE, Feng Z, Chavez D, et al. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A 2011;108:11223-11228.
215. Le SY, Chen JH, Sonenberg N, et al. Conserved tertiary structural elements in the 5' nontranslated region of cardiovirus, aphthovirus and hepatitis A virus RNAs. Nucleic Acids Res 1993;21:2445-2451.
216. Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985;122:226-233.
217. Lemon S. Hepatitis A virus: current concepts of the molecular virology, immunobiology and approaches to vaccine development. Rev Med Virol 1992;73-87.
218. Lemon SM. Inactivated hepatitis A vaccines. JAMA 1994;271:1363-1364.
219. Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 1994;67(Suppl 4):19-23.
220. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985;313:1059-1067.
221. Lemon SM, Binn LN. Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions. J Gen Virol 1985;66(Pt 11):2501-2505.
222. Lemon SM, Binn LN, Marchwicki RH. Radioimmunofocus assay for quantitation of hepatitis A virus in cell cultures. J Clin Microbiol 1983;17:834-839.
223. Lemon SM, Brown CD, Brooks DS, et al. Specific immunoglobulin M response to hepatitis A virus determined by solid-phase radioimmunoassay. Infect Immun 1980;28:927-936.
224. Lemon SM, Jansen RW, Newbold JE. Infectious hepatitis A virus particles produced in cell culture consist of three distinct types with different buoyant densities in CsCl. J Virol 1985;54:78-85.
225. Lemon SM, Murphy PC, Provost PJ, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis 1997;176:9-19.
226. Lemon SM, Murphy PC, Shields PA, et al. Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J Virol 1991;65:2056-2065.
227. Lemon SM, Murphy PC, Smith A, et al. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J Med Virol 1994;43:44-49.
228. Levin S, Hahn T. Interferon system in acute viral hepatitis. Lancet 1982;1:592-594.
229. Lewis JA, Armstrong ME, Larson VM, et al. Use of a live, attenuated hepatitis A vaccine to prepare a highly purified, formalin-inactivated hepatitis A vaccine. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:94-97.
230. Liaw YF, Yang CY, Chu CM, et al. Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak. Infection 1986;14:156-158.
231. Linemeyer DL, Menke JG, Martin-Gallardo A, et al. Molecular cloning and partial sequencing of hepatitis A viral cDNA. J Virol 1985;54:247-255.
232. Locarnini SA, Ferris AA, Lehmann NI, et al. The antibody response following hepatitis A infection. Intervirology 1977;8:309-318.
233. Locarnini SA, Gust ID, Ferris AA, et al. A prospective study of acute viral hepatitis with particular reference to hepatitis A. Bull World Health Organ 1976;54:199-206.
234. Lu L, Ching KZ, de Paula VS, et al. Characterization of the complete genomic sequence of genotype II hepatitis A virus (CF53/Berne isolate). J Gen Virol 2004;85:2943-2952.
235. MacCallum FO. Homologous serum jaundice. Lancet 1947;2:691-692.
236. MacCallum FO, Bradley WH. Transmission of infective hepatitis to human volunteers. Lancet 1944;2:228.
237. Mackiewicz V, Cammas A, Desbois D, et al. Nucleotide variability and translation efficiency of the 5' untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitis. J Virol 2010;84:10139-10147.
238. Mackiewicz V, Dussaix E, Le Petitcorps MF, et al. Detection of hepatitis A virus RNA in saliva. J Clin Microbiol 2004;42:4329-4331.
239. Maier K, Gabriel P, Koscielniak E, et al. Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol 1988;62:3756-3763.
240. Maiga MY, Oberti F, Rifflet H, et al. [Hematologic manifestations related to hepatitis A virus. 3 cases]. Gastroenterol Clin Biol 1997;21:327-330.
241. Malcolm BA. The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Protein Sci 1995;4:1439-1445.
242. Malcolm BA, Chin SM, Jewell DA, et al. Expression and characterization of recombinant hepatitis A virus 3C proteinase. Biochemistry 1992;31:3358-3363.
243. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994;120:1-7.
244. Mao JS, Dong DX, Zhang HY, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989;159:621-624.
245. Margolis HS, Nainan OV. Identification of virus components in circulating immune complexes isolated during hepatitis A virus infection. Hepatology 1990;11:31-37.
246. Margolis HS, Nainan OV, Krawczynski K, et al. Appearance of immune complexes during experimental hepatitis A infection in chimpanzees. J Med Virol 1988;26:315-326.
247. Martin A, Benichou D, Chao SF, et al. Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J Virol 1999;73:6220-6227.
248. Martin A, Escriou N, Chao SF, et al. Identification and site-directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts. Virology 1995;213:213-222.
249. Martin A, Lemon S. The molecular biology of hepatitis A virus. In: Ou J-H, ed. Hepatitis Viruses. Norwell, MA: Kluwer Academic Publishers; 2002:23-50.
250. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 2006;43(Suppl 1):S164-S172.
251. Marvil P, Knowles NJ, Mockett AP, et al. Avian encephalomyelitis virus is a picornavirus and is most closely related to hepatitis A virus. J Gen Virol 1999;80(Pt 3):653-662.
252. Mascoli CC, Ittensohn OL, Villarejos VM, et al. Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc Soc Exp Biol Med 1973;142:276-282.
253. Mathiesen LR, Drucker J, Lorenz D, et al. Localization of hepatitis A antigen in marmoset organs during acute infection with hepatitis A virus. J Infect Dis 1978;138:369-377.
254. Mathiesen LR, Moller AM, Purcell RH, et al. Hepatitis A virus in the liver and intestine of marmosets after oral inoculation. Infect Immun 1980;28:45-48.
255. Maynard JE. Viral hepatitis as an occupational hazard in the health care profession. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press; 1978:321-332.
256. Maynard JE, Bradley DW, Gravelle CR, et al. Preliminary studies of hepatitis A in chimpanzees. J Infect Dis 1975;131:194-197.
257. Maynard JE, Bradley DW, Hornbeck CL, et al. Preliminary serologic studies of antibody to hepatitis A virus in populations in the United States. J Infect Dis 1976;134:528-530.
258. Mbithi JN, Springthorpe VS, Sattar SA. Chemical disinfection of hepatitis A virus on environmental surfaces. Appl Environ Microbiol 1990;56:3601-3604.
259. McCaustland KA, Bond WW, Bradley DW, et al. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol 1982;16:957-958.
260. McDonald S. Acute yellow atrophy. Edinburgh Med J 1908;15:208.
261. McIntire JJ, Umetsu SE, Macaubas C, et al. Immunology: hepatitis A virus link to atopic disease. Nature 2003;425:576.
262. McKnight KL, Lemon SM. The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication. RNA 1998;4:1569-1584.
263. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:1771-1773.
264. Morace G, Pisani G, Beneduce F, et al. Mutations in the 3A genomic region of two cytopathic strains of hepatitis A virus isolated in Italy. Virus Res 1993;28:187-194.
265. Moratorio G, Costa-Mattioli M, Piovani R, et al. Bayesian coalescent inference of hepatitis A virus populations: evolutionary rates and patterns. J Gen Virol 2007;88:3039-3042.
266. Morse LJ, Bryan JA, Hurley JP, et al. The Holy Cross college football team hepatitis outbreak. JAMA 1972;219:706-708.
267. Mosley JW. Epidemiology of HAV infection. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press; 1978:85-104.
268. Mourani S, Dobbs SM, Genta RM, et al. Hepatitis A virus-associated cholecystitis. Ann Intern Med 1994;120:398-400.
269. Murphy BL, Maynard JE, Bradley DW, et al. Immunofluorescence of hepatitis A virus antigen in chimpanzees. Infect Immun 1978;21:663-665.
270. Murray R. Viral hepatitis. Bull N Y Acad Med 1955;31:341-358.
271. Nagaraju M, Weitzman S, Baumann G. Viral hepatitis and agranulocytosis. Am J Dig Dis 1973;18:247-252.
272. Nainan OV, Armstrong GL, Han XH, et al. Hepatitis A molecular epidemiology in the United States, 1996-1997: sources of infection and implications of vaccination policy. J Infect Dis 2005;191:957-963.
273. Nainan OV, Brinton MA, Margolis HS. Identification of amino acids located in the antibody binding sites of human hepatitis A virus. Virology 1992;191:984-987.
274. Nainan OV, Margolis HS, Robertson BH, et al. Sequence analysis of a new hepatitis A virus naturally infecting cynomolgus macaques (Macaca fascicularis). J Gen Virol 1991;72(Pt 7):1685-1689.
275. Najarian R, Caput D, Gee W, et al. Primary structure and gene organization of human hepatitis A virus. Proc Natl Acad Sci U S A 1985;82:2627-2631.
276. Neefe J, Gellis S, Stokes JJ. Homologous serum hepatitis and infectious (epidemic) hepatitis: studies in volunteers bearing on immunological and other characteristics of the biological agents. Am J Med 1946;1:3-22.
277. Neefe JR, Stokes JJ. An epidemic of infectious hepatitis apparently due to a water-borne agent. JAMA 1945;128:1975.
278. Niu MT, Salive M, Krueger C, et al. Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Clin Infect Dis 1998;26:1475-1476.
279. Noble RC, Kane MA, Reeves SA, et al. Posttransfusion hepatitis A in a neonatal intensive care unit. JAMA 1984;252:2711-2715.
280. Normann A, Jung C, Vallbracht A, et al. Time course of hepatitis A viremia and viral load in the blood of human hepatitis A patients. J Med Virol 2004;72:10-16.
281. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
282. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-275.
283. Ozaras R, Mert A, Yilmaz MH, et al. Acute viral cholecystitis due to hepatitis A virus infection. J Clin Gastroenterol 2003;37:79-81.
284. Palmenberg AC, Neubauer D, Skern T. Genome organization and encoded proteins. In: Ehrenfeld E, Domingo E, Roos RP, eds. The Picornaviruses. Washington, DC: ASM Press; 2010:3-17.
285. Parry JV, Mortimer PP. The heat sensitivity of hepatitis A virus determined by a simple tissue culture method. J Med Virol 1984;14:277-283.
286. Paul AV, Tada H, von der Helm K, et al. The entire nucleotide sequence of the genome of human hepatitis A virus (isolate MBB). Virus Res 1987;8:153-171.
287. Paul AV, van Boom JH, Filippov D, et al. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 1998;393:280-284.
288. Paul JR, Havens WP. Recent advances in the study of infectious hepatitis and serum jaundice. Trans Assoc Am Physicians 1946;59:133-141.
289. Paul JR, Havens WP, Sabin AB, et al. Transmission experiments in serum jaundice and infectious hepatitis. JAMA 1945;128:911-915.
290. Paulous S, Malnou CE, Michel YM, et al. Comparison of the capacity of different viral internal ribosome entry segments to direct translation initiation in poly(A)-dependent reticulocyte lysates. Nucleic Acids Res 2003;31:722-733.
291. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 1992;10(Suppl 1):S99-S101.
292. Perez-Sautu U, Costafreda MI, Cayla J, et al. Hepatitis A virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis 2011;17:734-737.
293. Peters H, Kusov YY, Meyer S, et al. Hepatitis A virus proteinase 3C binding to viral RNA: correlation with substrate binding and enzyme dimerization. Biochem J 2005;385:363-370.
294. Peterson DA, Hurley TR, Hoff JC, et al. Effect of chlorine treatment on infectivity of hepatitis A virus. Appl Environ Microbiol 1983;45:223-227.
295. Piazza M, Safary A, Vegnente A, et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 1999;17:585-588.
296. Ping LH, Jansen RW, Stapleton JT, et al. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A 1988;85:8281-8285.
297. Ping LH, Lemon SM. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol 1992;66:2208-2216.
298. Pinto MA, Marchevsky RS, Baptista ML, et al. Experimental hepatitis A virus (HAV) infection in Callithrix jacchus: early detection of HAV antigen and viral fate. Exp Toxicol Pathol 2002;53:413-420.
299. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-1197.
300. Probst C, Jecht M, Gauss-Muller V. Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A. J Biol Chem 1999;274:4527-4531.
301. Probst C, Jecht M, Gauss-Muller V. Processing of proteinase precursors and their effect on hepatitis A virus particle formation. J Virol 1998;72:8013-8020.
302. Provost PJ, Banker FS, Giesa PA, et al. Progress toward a live, attenuated human hepatitis A vaccine. Proc Soc Exp Biol Med 1982;170:8-14.
303. Provost PJ, Emini EA, Lewis JA, et al. Progress toward the development of a hepatitis A vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss; 1988:83-86.
304. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979;160:213-221.
305. Provost PJ, Wolanski BS, Miller WJ, et al. Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326 (38578). Proc Soc Exp Biol Med 1975;148:532-539.
306. Purcell RH, D'Hondt E, Bradbury R, et al. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 1992;10(Suppl 1):S148-S151.
307. Purcell RH, Emerson SU. Animal models of hepatitis A and E. ILAR J 2001;42:161-177.
308. Purcell RH, Emerson SU. Hepatitis A virus pathogenesis and attenuation. In: Semler BL, Wimmer E, eds. Molecular Biology of Picornaviruses. Washington, DC: American Society for Microbiology Press; 2002:415-425.
309. Purcell RH, Feinstone SM, Ticehurst JR, et al. Hepatitis A virus. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. Orlando, FL: Grune & Stratton; 1984:9-22.
310. Qu L, Feng Z, Yamane DY, et al. Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog 2011;7:e1002169.
311. Rakela J, Mosley JW. Fecal excretion of hepatitis A virus in humans. J Infect Dis 1977;135:933-938.
312. Raychaudhuri G, Govindarajan S, Shapiro M, et al. Utilization of chimeras between human (HM-175) and simian (AGM-27) strains of hepatitis A virus to study the molecular basis of virulence. J Virol 1998;72:7467-7475.
313. Repsher LH, Freebern RK. Effects of early and vigorous exercise on recovery from infectious hepatitis. N Engl J Med 1969;281:1393-1396.
314. Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003;38:613-618.
315. Robertson BH, Alter MJ, Bell BP, et al. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Biologicals 1998;26:95-99.
316. Robertson BH, Averhoff F, Cromeans TL, et al. Genetic relatedness of hepatitis A virus isolates during a community-wide outbreak. J Med Virol 2000;62:144-150.
317. Robertson BH, D'Hondt EH, Spelbring J, et al. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection. J Med Virol 1994;43:249-251.
318. Robertson BH, Jansen RW, Khanna B, et al. Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol 1992;73(Pt 6):1365-1377.
319. Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991;164:476-482.
320. Rozen P, Korn RJ, Zimmerman HJ. Computer analysis of liver function tests and their interrelationships in 347 cases of viral hepatitis. Isr J Med Sci 1970;6:67-79.
321. Ruddy SJ, Johnson RF, Mosley JW, et al. An epidemic of clam-associated hepatitis. JAMA 1969;208:649-655.
322. Sanchez G, Bosch A, Pinto RM. Genome variability and capsid structural constraints of hepatitis A virus. J Virol 2003;77:452-459.
323. Sanchez G, Pinto RM, Vanaclocha H, et al. Molecular characterization of hepatitis A virus isolates from a transcontinental shellfish-borne outbreak. J Clin Microbiol 2002;40:4148-4155.
324. Schenzle D, Dietz K, Frosner GG. Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. Am J Epidemiol 1979;110:70-76.
325. Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992;10(Suppl 1):S18-S20.
326. Schofield DJ, Satterfield W, Emerson SU, et al. Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus. Virology 2002;292:127-136.
327. Scholz E, Heinricy U, Flehmig B. Acid stability of hepatitis A virus. J Gen Virol 1989;70(Pt 9):2481-2485.
328. Schulman AN, Dienstag JL, Jackson DR, et al. Hepatitis A antigen particles in liver, bile, and stool of chimpanzees. J Infect Dis 1976;134:80-84.
329. Schulte I, Hitziger T, Giugliano S, et al. Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection. J Hepatol 2011;54:201-208.
330. Schultheiss T, Sommergruber W, Kusov Y, et al. Cleavage specificity of purified recombinant hepatitis A virus 3C proteinase on natural substrates. J Virol 1995;69:1727-1733.
331. Schultz DE, Hardin CC, Lemon SM. Specific interaction of glyceraldehyde 3-phosphate dehydrogenase with the 5'-nontranslated RNA of hepatitis A virus. J Biol Chem 1996;271:14134-14142.
332. Schultz DE, Honda M, Whetter LE, et al. Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J Virol 1996;70:1041-1049.
333. Schweitzer IL, Weiner JM, McPeak CM, et al. Oral contraceptives in acute viral hepatitis. JAMA 1975;233:979-980.
334. Sciot R, Van Damme B, Desmet VJ. Cholestatic features in hepatitis A. J Hepatol 1986;3:172-181.
335. Scotto J, Opolon P, Eteve J, et al. Liver biopsy and prognosis in acute liver failure. Gut 1973;14:927-933.
336. Shaffer DR, Brown EA, Lemon SM. Large deletion mutations involving the first pyrimidine-rich tract of the 5' nontranslated RNA of human hepatitis A virus define two adjacent domains associated with distinct replication phenotypes. J Virol 1994;68:5568-5578.
337. Shaffer DR, Emerson SU, Murphy PC, et al. A hepatitis A virus deletion mutant which lacks the first pyrimidine-rich tract of the 5' nontranslated RNA remains virulent in primates after direct intrahepatic nucleic acid transfection. J Virol 1995;69:6600-6604.
338. Shaffer DR, Lemon SM. Temperature-sensitive hepatitis A virus mutants with deletions downstream of the first pyrimidine-rich tract of the 5' nontranslated RNA are impaired in RNA synthesis. J Virol 1995;69:6498-6506.
339. Shimizu YK, Mathiesen LR, Lorenz D, et al. Localization of hepatitis A antigen in liver tissue by peroxidase-conjugated antibody method: light and electron microscopic studies. J Immunol 1978;121:1671-1679.
340. Shouval D. Module 18: hepatitis A. In: The immunological basis for immunization series. Geneva, Switzerland, World Health Organization; 2011:1-39.
341. Shouval D, Ashur Y, Adler R, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 1993;11(Suppl 1):S9-S14.
342. Siegl G, Frosner GG, Gauss-Muller V, et al. The physicochemical properties of infectious hepatitis A virions. J Gen Virol 1981;57:331-341.
343. Siegl G, Weitz M. Pathogenesis of hepatitis A: persistent viral infection as basis of an acute disease? Microb Pathog 1993;14:1-8.
344. Siegl G, Weitz M, Kronauer G. Stability of hepatitis A virus. Intervirology 1984;22:218-226.
345. Silberstein E, Konduru K, Kaplan GG. The interaction of hepatitis A virus (HAV) with soluble forms of its cellular receptor 1 (HAVCR1) share the physiological requirements of infectivity in cell culture. Virol J 2009;6:175.
346. Silberstein E, Xing L, van de Beek W, et al. Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin- and mucin-like regions. J Virol 2003;77:8765-8774.
347. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-226.
348. Skinhoj P, Mikkelsen F, Hollinger FB. Hepatitis A in Greenland: importance of specific antibody testing in epidemiologic surveillance. Am J Epidemiol 1977;105:140-147.
349. Smith FR, Henkin RI, Dell RB. Disordered gustatory acuity in liver disease. Gastroenterology 1976;70:568-571.
350. Sobsey MD, Shields PA, Hauchman FS, et al. Survival and persistence of hepatitis A virus in environmental samples. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss; 1988:121-124.
351. Stanway G, Brown F, Christian P, et al. Family Picornaviridae. In: Fauquet CM, Mayo MA, Maniloff J, et al, eds. Virus Taxonomy, VIIIth Report of the ICTV. London: Elsevier/Academic Press; 2005:757-778.
352. Stapleton JT, Frederick J, Meyer B. Hepatitis A virus attachment to cultured cell lines. J Infect Dis 1991;164:1098-1103.
353. Stapleton JT, Jansen R, Lemon SM. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology 1985;89:637-642.
354. Stapleton JT, Lemon SM. Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol 1987;61:491-498.
355. Steffen R. Risk of hepatitis A in travellers. Vaccine 1992;10(Suppl 1):S69-S72.
356. Steil BP, Barton DJ. Cis-active RNA elements (CREs) and picornavirus RNA replication. Virus Res 2009;139:240-252.
357. Stokes J, Jr., Farquhar JA, Drake ME, et al. Infectious hepatitis; length of protection by immune serum globulin (gamma globulin) during epidemics. J Am Med Assoc 1951;147:714-719.
358. Stokes JJ, Neefe J. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945;127:144-145.
359. Stravitz TR, Kramer DJ. Acute liver failure. In: Boyer TD, Manns MP, Sanyal AJ, eds. Zakim & Boyer's Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia: Saunders; 2012:327-351.
360. Szmuness W, Dienstag JL, Purcell RH, et al. Distribution of antibody to hepatitis A antigen in urban adult populations. N Engl J Med 1976;295:755-759.
361. Szmuness W, Dienstag JL, Purcell RH, et al. The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol 1977;106:392-398.
362. Tami C, Silberstein E, Manangeeswaran M, et al. Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions. J Virol 2007;81:3437-3446.
363. Tassopoulos N, Papaevangelou G, Roumeliotou-Karayannis A, et al. Double infections with hepatitis A and B viruses. Liver 1985;5:348-353.
364. Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, et al. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 1986;154:231-237.
365. Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006;44:1589-1597.
366. Tesar M, Harmon SA, Summers DF, et al. Hepatitis A virus polyprotein synthesis initiates from two alternative AUG codons. Virology 1992;186:609-618.
367. Tesar M, Jia XY, Summers DF, et al. Analysis of a potential myristoylation site in hepatitis A virus capsid protein VP4. Virology 1993;194:616-626.
368. Tesar M, Pak I, Jia XY, et al. Expression of hepatitis A virus precursor protein P3 in vivo and in vitro: polyprotein processing of the 3CD cleavage site. Virology 1994;198:524-533.
369. Teterina NL, Bienz K, Egger D, et al. Induction of intracellular membrane rearrangements by HAV proteins 2C and 2BC. Virology 1997;237:66-77.
370. Thompson P, Lu J, Kaplan GG. The Cys-rich region of hepatitis A virus cellular receptor 1 is required for binding of hepatitis A virus and protective monoclonal antibody 190/4. J Virol 1998;72:3751-3761.
371. Tjon GM, Coutinho RA, van den Hoek A, et al. High and persistent excretion of hepatitis A virus in immunocompetent patients. J Med Virol 2006;78:1398-1405.
372. Tjon GM, Wijkmans CJ, Coutinho RA, et al. Molecular epidemiology of hepatitis A in Noord-Brabant, The Netherlands. J Clin Virol 2005;32:128-136.
373. Tozun N, Forbes A, Anderson MG, et al. Safety of alcohol after viral hepatitis. Lancet 1991;337:1079-1080.
374. Troisi CL, Hollinger FB, Krause DS, et al. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. Vaccine 1997;15:1613-1617.
375. Trump BF, Kim KM, Iseri OA. Cellular pathophysiology of hepatitis. Am J Clin Pathol 1976;65:828-847.
376. Tsarev SA, Emerson SU, Balayan MS, et al. Simian hepatitis A virus (HAV) strain AGM-27: comparison of genome structure and growth in cell culture with other HAV strains. J Gen Virol 1991;72(Pt 7):1677-1683.
377. Usonis V, Bakasenas V, Valentelis R, et al. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 2003;21:4588-4592.
378. Vallbracht A, Fleischer B. Immune pathogenesis of hepatitis A. Arch Virol Suppl 1992;4:3-4.
379. Vallbracht A, Gabriel P, Maier K, et al. Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology 1986;6:1308-1314.
380. Vallbracht A, Maier K, Stierhof YD, et al. Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 1989;160:209-217.
381. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994;44:446-451.
382. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290.
383. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007;357:1685-1694.
384. Vidor E, Dumas R, Porteret V, et al. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 2004;23:300-309.
385. Wagner G, Lavanchy D, Darioli R, et al. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 1993;11:1027-1032.
386. Ward R, Krugman S, Giles JP, et al. Infectious hepatitis; studies of its natural history and prevention. N Engl J Med 1958;258:407-416.
387. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005;294:194-201.
388. Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983;309:147-150.
389. Weitz M, Baroudy BM, Maloy WL, et al. Detection of a genome-linked protein (VPg) of hepatitis A virus and its comparison with other picornaviral VPgs. J Virol 1986;60:124-130.
390. Weitz M, Siegl G. Variation among hepatitis A virus strains. I. Genomic variation detected by T1 oligonucleotide mapping. Virus Res 1985;4:53-67.
391. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-457.
392. Werzberger A, Mensch B, Nalin DR, et al. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 2002;20:1699-1701.
393. Wheeler C, Vogt TM, Armstrong GL, et al. An outbreak of hepatitis A associated with green onions. N Engl J Med 2005;353:890-897.
394. Wheeler CM, Fields HA, Schable CA, et al. Adsorption, purification, and growth characteristics of hepatitis A virus strain HAS-15 propagated in fetal rhesus monkey kidney cells. J Clin Microbiol 1986;23:434-440.
395. Wheelock EF, Schenker S, Combes B. Absence of circulating interferon in patients with infectious and serum hepatitis. Proc Soc Exp Biol Med 1968;128:251-253.
396. Whetter LE, Day SP, Elroy-Stein O, et al. Low efficiency of the 5' nontranslated region of hepatitis A virus RNA in directing cap-independent translation in permissive monkey kidney cells. J Virol 1994;68:5253-5263.
397. Widell A, Hansson BG, Oberg B, et al. Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus. Antiviral Res 1986;6:103-112.
398. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996;49:235-241.
399. Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998;128:111-114.
400. Winokur PL, McLinden JH, Stapleton JT. The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles. J Virol 1991;65:5029-5036.
401. World Health Organization. Viral hepatitis: report of WHO Scientific Group. WHO Tech Rep Ser 1973;512:7-52.
402. Xu Z, Wang X, Li R, et al. [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H2 strains and LA-1 strains)]. Zhonghua Yi Xue Za Zhi 2002;82:678-681.
403. Yang L, Kiyohara T, Kanda T, et al. Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virol J 2010;7:212.
404. Yang Y, Liang Y, Qu L, et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci U S A 2007;104:7253-7258.
405. Yang Y, Yi M, Evans DJ, et al. Identification of a conserved RNA replication element (cre) within the 3Dpol-coding sequence of hepatoviruses. J Virol 2008;82:10118-10128.
406. Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:76-78.
407. Yi M, Lemon SM. Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells. J Virol 2002;76:1171-1180.
408. Yi M, Schultz DE, Lemon SM. Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function. J Virol 2000;74:6459-6468.
409. Yin J, Cherney MM, Bergmann EM, et al. An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors. J Mol Biol 2006;361:673-686.
410. Yotsuyanagi H, Iino S, Koike K, et al. Duration of viremia in human hepatitis A viral infection as determined by polymerase chain reaction. J Med Virol 1993;40:35-38.
411. Zachoval R, Abb J, Zachoval V, et al. Circulating interferon in patients with acute hepatitis A. J Infect Dis 1986;153:1174-1175.
412. Zajac AJ, Amphlett EM, Rowlands DJ, et al. Parameters influencing the attachment of hepatitis A virus to a variety of continuous cell lines. J Gen Virol 1991;72(Pt 7):1667-1675.
413. Zhang B, Morace G, Gauss-Muller V, et al. Poly(A) binding protein, C-terminally truncated by the hepatitis A virus proteinase 3C, inhibits viral translation. Nucleic Acids Res 2007;35:5975-5984.
414. Zhang B, Seitz S, Kusov Y, et al. RNA interaction and cleavage of poly(C)-binding protein 2 by hepatitis A virus protease. Biochem Biophys Res Commun 2007;364:725-730.
415. Zhang H, Chao SF, Ping LH, et al. An infectious cDNA clone of a cytopathic hepatitis A virus: genomic regions associated with rapid replication and cytopathic effect. Virology 1995;212:686-697.
416. Zhang Y, Kaplan GG. Characterization of replication-competent hepatitis A virus constructs containing insertions at the N terminus of the polyprotein. J Virol 1998;72:349-357.
417. Zhou Y, Callendret B, Xu D, et al. Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 2012;209:1481-1492.
418. Zhuang FC, Qian W, Mao ZA, et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chin Med J (Engl) 2005;118:1851-1856.
419. Zuckerman A. The history of viral hepatitis from antiquity to the present. In: Deinhardt F, Deinhardt J, eds. Viral Hepatitis: Laboratory and Clinical Science. New York: Marcel Dekker; 1983:3-32.
420. Zuckerman AJ. The clinical and laboratory features of acute hepatitis in the Royal Air Force. Mon Bull Minist Health Public Health Lab Serv 1965;24:340-346.